Klotho Neurosciences, Inc. has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc., a company focused on induced pluripotent stem cells (iPSC) and cellular reprogramming. The proposed transaction is subject to customary closing conditions.  Under the LOI, Klotho would acquire Turn’s ERA (Epigenetic Reprogramming of Age) platform and eTurna RNA delivery system. These technologies are designed to rejuvenate somatic cells and restore tissue function, cr...